BTIG initiated coverage of Oncology Institute (TOI) with a Buy rating and $7 price target The company specializes in the treatment and management of cancer patients through a blend of both fee-for-service, capitated, and value-based-care contracts, the analyst tells investors in a research note. The firm says that with the aging of America and rising complex care cost trends amongst some health plans, especially in Medicare Advantage, fee-for-service revenue within Oncology Institute will rise through 2025. Demand for capitated and managed care, sub-contracted risk will likely increase as well, contends BTIG.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TOI:
- The Oncology Institute’s Strong Q1 2025 Performance
- The Oncology Institute names Jeffrey Langsam chief clinical officer
- The Oncology Institute files to sell 27.92M shares of common stock for holders
- Oncology Institute Holds Annual Stockholders Meeting
- The Oncology Institute to present at ASCO meeting on its cancer care model